Biogen Stock News

Save(0) Please login to bookmark Username or Email Address Password Remember Me Swiss pharmaceutical company Biogen has won discovery of documents sent from Sandoz to [] Subscribe for instant access to all Lawyerly content. Already a subscriber? Username or Email Address Password Remember Me Lost your password? Want to test drive Lawyerly? Contact us to take a free trial. The post Biogen wins discovery for potential IP lawsuit against Sandoz appeared first on Lawyerly .

An advisory panel to the Japanese drug regulator is continuing deliberations on the new drug application filed by Biogen Inc. BIIB, -0.97% and partner Eisai Co. Ltd ESALY, +0.69% 4523, +1.21% , the co

Biogen (NASDAQ:BIIB) had its price target lowered by investment analysts at SVB Leerink from $450.00 to $325.00 in a research note issued on Monday, Price Targets.com reports. The firm currently has an outperform rating on the biotechnology companys stock. SVB Leerinks price target would indicate a potential upside of 38.50% from the companys previous close. []

Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200. Over []

Lipe & Dalton lowered its position in Biogen Inc. (NASDAQ:BIIB) by 0.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,005 shares of the biotechnology company’s stock after selling 70 shares during the period. Biogen comprises approximately 1.5% of Lipe & Dalton’s holdings, making the stock […]

Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022

Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm in half starting Jan. 1 is “a day late and a dollar short,” according to Raymond James, which is not expecting the move to c

The moves follow a disappointing commercial launch of Aduhelm, as well as anger over the drugs high price.

In a surprise move, Biogen Inc (NASDAQ: BIIB) announced that it would slash the price of its controversial Alzheimer's drug Aduhelm in half from $56,000 to $28,000. In Q3, Biogen generated a mere

Biogen Inc. BIIB, +0.81% said Monday it will reduce the price of its Alzheimer's drug aduhelm by 50% starting Jan. 1 in an effort to get it to more patients with early signs of the disease. "For a pat

Related Stocks: ANTM , TGT , CL , MCK , GS , BIIB , MRNA , KSS , SBUX , ZBRA , IPG , MMM , PG , LLY , HON , ADSK , MRK , HLT , MO , BBY , ODFL , HUM , HPQ , LOW ,

TCI Wealth Advisors Inc. lessened its position in Biogen Inc. (NASDAQ:BIIB) by 26.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 814 shares of the biotechnology companys stock after selling 292 shares during the quarter. TCI Wealth Advisors Inc.s holdings in Biogen were []

Texas Permanent School Fund lowered its holdings in Biogen Inc. (NASDAQ:BIIB) by 7.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,024 shares of the biotechnology companys stock after selling 1,988 shares during the period. Texas Permanent School Funds []

Related Stocks: PYPL , EA , PLNT , UPS , CRM , BIIB , LYV , REGN , UNH , EOG , MA , FCX , MMM , BABA , MRK , FDX ,

Equities analysts forecast that Biogen Inc. (NASDAQ:BIIB) will announce sales of $2.63 billion for the current quarter, Zacks Investment Research reports. Twenty Nine analysts have issued estimates for Biogens earnings, with estimates ranging from $2.54 billion to $2.78 billion. Biogen posted sales of $2.85 billion during the same quarter last year, which would suggest a []